POLYMORPHE FORMEN

European patent · EP3004100 · In force

Register entry

Publication number
EP3004100
Application number
EP14804859
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 28, 2014
Published
Apr 13, 2016
Granted
Jun 27, 2018
Protection ends at the latest
May 27, 2034
Next annual fee due
May 31, 2027
IPC classes
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 5/00 (2006.01)
A61P 43/00 (2006.01)
Priority
US 201361827958 P 28.05.2013
PCT application
PCT/JP2014/002819 28.05.2014
PCT publication
WO2014/192294 04.12.2014
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

capromorelini tartras

C03004100/01 · Medicine · Granted · Protection from May 28, 2034 to Aug 6, 2038

Authorisation 68874 (Swissmedic, Aug 7, 2023)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  4. Jun 2, 2023

    Change

    Published in Swissreg on 02.06.2023

  5. Jun 27, 2018

    Granted

    Published in Swissreg on 27.06.2018

Parties

Holder

RaQualia Pharma Inc.

1-21-19, Meieki Minami Nakamura-ku, Nagoya-shi Aichi 450-0003, JP

Inventor

SUDO, Masaki

Nagoya-shi Aichi 450-0003, JP

SHIMADA, Kaoru

Nagoya-shi Aichi 450-0003, JP

WAKABAYASHI, Hiroaki

Nagoya-shi Aichi 450-0003, JP

NUMATA, Toyoharu

Nagoya-shi Aichi 450-0003, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.